ENvue Medical Secures $2.5M Investment by Amending Preferred Stock Terms
Summary
ENvue Medical amended its Series H Convertible Preferred Stock terms, removing the floor price in exchange for a $2.5 million additional investment, significantly boosting its capital.
Key Events
-
Material Agreement Amendment
The company entered into an Amendment Agreement with holders of its Series H Convertible Preferred Stock on January 30, 2026.
-
Removal of Preferred Stock Floor Price
The amendment removes the 'Floor Price' from the Certificate of Designations for the Series H Convertible Preferred Stock, potentially allowing for conversion at lower prices.
-
Significant Capital Infusion
In consideration for the amendment, the preferred stockholders exercised an 'Additional Investment Right' of $2,500,000, providing substantial new capital to the company.
Analysis
ENvue Medical, a micro-cap company, has secured a substantial $2.5 million capital injection by agreeing to amend the terms of its Series H Convertible Preferred Stock. This amendment removes the 'Floor Price' for conversion, which could lead to increased dilution for common shareholders if the stock price declines. However, the immediate infusion of $2.5 million is a critical liquidity event for a company with a market capitalization of approximately $3.5 million, providing essential operational runway.
At the time of this filing, FEED was trading at $3.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.99 to $162.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.